Overview of Tumor Cell–Based Vaccines

REFERENCES

• D. Jocham, A. Richter, L. Hoffmann, K. Iwig, D. Fahlenkamp, G. Zakrzewski, E. Schmitt, T. Dannenberg, W. Lehmacher, J. von Wietersheim, and C. Doehn, Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial, Lancet, 363(9409): 594–599, 2004. [CSA]
   PubMed Web of Science ®Google Scholar
• C.A. Uyl-de Groot, J.B. Vermorken, M.G. Hanna, Jr., P. Verboom, M.T. Groot, G.J. Bonsel, C.J. Meijer, and H.M. Pinedo, Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: A prospective study of medical and economic benefits, Vaccine, 23(17–18): 2379–2387, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• L. Shen and K.L. Rock, Priming of T cells by exogenous antigen cross-presented on MHC class I molecules, Curr. Opin. Immunol., 18(1): 85–91, 2006. [CSA], [CROSSREF]
   Google Scholar
• M.C. Wolkers, G. Stoetter, F.A. Vyth-Dreese, and T.N. Schumacher, Redundancy of direct priming and cross-priming in tumor-specific CD + T cell responses, J. Immunol., 167(7): 3577–3584, 2001. [CSA]
   Google Scholar
• A.Y. Huang, P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky, Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens, Science, 264(5161): 961–965, 1994. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.M. Thomas, L.M. Santarsiero, E.R. Lutz, T.D. Armstrong, Y.C. Chen, L.Q. Huang, D.A. Laheru, M. Goggins, R.H. Hruban, and E.M. Jaffee, Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients, J. Exp. Med., 200(3): 297–306, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M. Nouri-Shirazi, J. Banchereau, D. Bell, S. Burkeholder, E.T. Kraus, J. Davoust, and K.A. Palucka, Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses, J. Immunol., 165(7): 3797–3803, 2000. [CSA]
   PubMed Web of Science ®Google Scholar
• A.F. Ochsenbein, P. Klenerman, U. Karrer, B. Ludewig, M. Pericin, H. Hengartner, and R.M. Zinkernagel, Immune surveillance against a solid tumor fails because of immunological ignorance, Proc. Natl. Acad. Sci. U.S.A., 96(5): 2233–2238, 1999. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.F. Ochsenbein, S. Sierro, B. Odermatt, M. Pericin, U. Karrer, J. Hermans, S. Hemmi, H. Hengartner, and R.M. Zinkernagel, Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction, Nature, 411(6841): 1058–1064, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• L. Qi, J.M. Rojas, and S. Ostrand-Rosenberg, Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo, J. Immunol., 165(10): 5451–5461, 2000. [CSA]
   PubMed Web of Science ®Google Scholar
• T.D. Armstrong, V.K. Clements, and S. Ostrand-Rosenberg, MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4 + T lymphocytes, J. Immunol., 160(2): 661–666, 1998. [CSA]
   PubMed Web of Science ®Google Scholar
• R.O. Dillman, C. DeLeon, L.D. Beutel, N.M. Barth, L.S. Schwartzberg, L.E. Spitler, D.H. Garfield, A.A. O'Connor, and S.K. Nayak, Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma, Crit. Rev. Oncol. Hematol., 39(1–2): 115–123, 2001. [CSA]
   PubMed Web of Science ®Google Scholar
• J. Nakashima, M. Tachibana, Y. Horiguchi, M. Oya, T. Ohigashi, H. Asakura, and M. Murai, Serum interleukin 6 as a prognostic factor in patients with prostate cancer, Clin. Cancer Res., 6(7): 2702–2706, 2000. [CSA]
   PubMed Web of Science ®Google Scholar
• T. Nishimura, K. Iwakabe, M. Sekimoto, Y. Ohmi, T. Yahata, M. Nakui, T. Sato, S. Habu, H. Tashiro, M. Sato, and A. Ohta, Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo, J. Exp. Med., 190(5): 617–627, 1999. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• F. Fallarino, U. Grohmann, R. Bianchi, C. Vacca, M.C. Fioretti, and P. Puccetti, Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8 + T cell-dependent tumor eradication in vivo, J. Immunol., 165(10): 5495–5501, 2000. [CSA]
   Google Scholar
• D.R. Surman, M.E. Dudley, W.W. Overwijk, and N.P. Restifo, Cutting edge: CD4 + T cell control of CD8 + T cell reactivity to a model tumor antigen, J. Immunol., 164(2): 562–565, 2000. [CSA]
   PubMed Web of Science ®Google Scholar
• D. Berd, H.C. Maguire, Jr., P. McCue, and M.J. Mastrangelo, Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients, J. Clin. Oncol., 8(11): 1858–1867, 1990. [CSA]
   PubMed Web of Science ®Google Scholar
• A. Baars, A.M. Claessen, A.J. van den Eertwegh, H.E. Gall, A.G. Stam, S. Meijer, G. Giaccone, C.J. Meijer, R.J. Scheper, J. Wagstaff, J.B. Vermorken, and H.M. Pinedo, Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: Experience in 81 patients, Ann. Oncol., 11(8): 965–970, 2000. [CSA], [CROSSREF]
   Google Scholar
• J.B. Vermorken, A.M. Claessen, H. van Tinteren, H.E. Gall, R. Ezinga, S. Meijer, R.J. Scheper, C.J. Meijer, E. Bloemena, J.H. Ransom, M.G. Hanna, Jr., and H.M. Pinedo, Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial, Lancet, 353(9150): 345–350, 1999. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• B.C. Knight, B.E. Souberbielle, G.P. Rizzardi, S.E. Ball, and A.G. Dalgleish, Allogeneic murine melanoma cell vaccine: A model for the development of human allogeneic cancer vaccine, Melanoma Res., 6(4): 299–306, 1996. [CSA]
   Google Scholar
• M.C. Labarthe, N. Halanek, L. Birchall, N. Russell, C. Desel, S. Todryk, M.J. Peters, A. Lucas, F.W. Falkenberg, A.G. Dalgleish, M. Whelan, and S.J. Ward, The biological effects of syngeneic and allogeneic cytokine-expressing prophylactic whole cell vaccines and the influence of irradiation in a murine melanoma model, Cancer Immunol. Immunother., 55(3): 277–288, 2006. [CSA], [CROSSREF]
   Google Scholar
• E. Wang, R. Lichtenfels, J. Bukur, Y. Ngalame, M.C. Panelli, B. Seliger, and F.M. Marincola, Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer, Cancer Res., 64(20): 7279–7287, 2004. [CSA], [CROSSREF]
   Google Scholar
• J.D. Eaton, M.J. Perry, S. Nicholson, M. Guckian, N. Russell, M. Whelan, and R.S. Kirby, Allogeneic whole-cell vaccine: A phase I/II study in men with hormone-refractory prostate cancer, BJU Int., 89(1): 19–26, 2002. [CSA]
   Google Scholar
• M.S. Mitchell, J. Kan-Mitchell, R.A. Kempf, W. Harel, H.Y. Shau, and S. Lind, Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant, Cancer Res., 48(20): 5883–5893, 1988. [CSA]
   PubMed Web of Science ®Google Scholar
• D.L. Morton, L.J. Foshag, D.S. Hoon, J.A. Nizze, E. Famatiga, L.A. Wanek, C. Chang, D.G. Davtyan, R.K. Gupta, R. Elashoff, , et al., Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine, Ann. Surg., 216(4): 463–482, 1992. [CSA]
   PubMed Web of Science ®Google Scholar
• R. Vilella, D. Benitez, J. Mila, A. Vilalta, R. Rull, F. Cuellar, C. Conill, S. Vidal-Sicart, J. Costa, E. Yachi, J. Palou, J. Malvehy, S. Puig, R. Marti, B. Mellado, and T. Castel, Treatment of patients with progressive unresectable metastatic melanoma with a heterologous polyvalent melanoma whole cell vaccine, Int. J. Cancer, 106(4): 626–631, 2003. [CSA], [CROSSREF]
   Google Scholar
• A. Michael, G. Ball, N. Quatan, F. Wushishi, N. Russell, J. Whelan, P. Chakraborty, D. Leader, M. Whelan, and H. Pandha, Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables, Clin. Cancer Res., 11(12): 4469–4478, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• E.C. Hsueh, R. Essner, L.J. Foshag, D.W. Ollila, G. Gammon, S.J. O'Day, P.D. Boasberg, S.L. Stern, X. Ye, and D.L. Morton, Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine, J. Clin. Oncol., 20(23): 4549–4554, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• E.C. Hsueh, L. Nathanson, L.J. Foshag, R. Essner, J.A. Nizze, S.L. Stern, and D.L. Morton, Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases, Cancer, 85(10): 2160–2169, 1999. [CSA], [CROSSREF]
   Google Scholar
• E.C. Hsueh, R.K. Gupta, K. Qi, and D.L. Morton, Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine, J. Clin. Oncol., 16(9): 2913–2920, 1998. [CSA]
   PubMed Web of Science ®Google Scholar
• K. Lang, F. Entschladen, C. Weidt, and K.S. Zaenker, Tumor immune escape mechanisms: Impact of the neuroendocrine system, Cancer Immunol. Immunother., 55(7): 749–760, 2006. [CSA], [CROSSREF]
   Google Scholar
• J.N. Cormier, M.C. Panelli, J.A. Hackett, M.P. Bettinotti, A. Mixon, J. Wunderlich, L.L. Parker, N.P. Restifo, S. Ferrone, and F.M. Marincola, Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model, Int. J. Cancer, 80(5): 781–790, 1999. [CSA], [CROSSREF]
   Google Scholar
• Y. Li, P. McGowan, I. Hellstrom, K.E. Hellstrom, and L. Chen, Costimulation of tumor-reactive CD4 + and CD8 + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma, J Immunol., 153(1): 421–428, 1994. [CSA]
   Google Scholar
• L. Chen, S. Ashe, W.A. Brady, I. Hellstrom, K.E. Hellstrom, J.A. Ledbetter, P. McGowan, and P.S. Linsley, Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4, Cell, 71(7): 1093–1102, 1992. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• S. Baskar, N. Nabavi, L.H. Glimcher, and S. Ostrand-Rosenberg, Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity, J. Immunother., 14(3): 209–215, 1993. [CSA]
   Google Scholar
• S.E. Townsend and J.P. Allison, Tumor rejection after direct costimulation of CD8 + T cells by B7-transfected melanoma cells, Science, 259(5093): 368–370, 1993. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D.J. Schendel, B. Frankenberger, P. Jantzer, S. Cayeux, E. Nobetaner, G. Willimsky, B. Maget, H. Pohla, and T. Blankenstein, Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse, Gene Ther., 7(23): 2007–2014, 2000. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• G.C. Meyer, R. Batrla, W. Rudy, S.C. Meuer, D. Wallwiener, B. Guckel, and U. Moebius, Potential of CD80-transfected human breast carcinoma cells to induce peptide-specific T lymphocytes in an allogeneic human histocompatibility leukocyte antigens (HLA)-A2.1 + -matched situation, Cancer Gene Ther., 6(3): 282–288, 1999. [CSA], [CROSSREF]
   Google Scholar
• M.A. Imro, P. Dellabona, S. Manici, S. Heltai, G. Consogno, M. Bellone, C. Rugarli, and M.P. Protti, Human melanoma cells transfected with the B7-2 co-stimulatory molecule induce tumor-specific CD8 + cytotoxic T lymphocytes in vitro, Hum. Gene Ther., 9(9): 1335–1344, 1998. [CSA]
   Google Scholar
• A. Dols, J.W. Smith, 2nd, S.L. Meijer, B.A. Fox, H.M. Hu, E. Walker, S. Rosenheim, T. Moudgil, T. Doran, W. Wood, M. Seligman, W.G. Alvord, D. Schoof, and W.J. Urba, Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: Clinical and immunological results, Hum. Gene. Ther., 14(11): 1117–1123, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• L.E. Raez, P.A. Cassileth, J.J. Schlesselman, K. Sridhar, S. Padmanabhan, E.Z. Fisher, P.A. Baldie, and E.R. Podack, Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer, J. Clin. Oncol., 22(14): 2800–2807, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• S.J. Antonia, J. Seigne, J. Diaz, C. Muro-Cacho, M. Extermann, M.J. Farmelo, M. Friberg, M. Alsarraj, J.J. Mahany, J. Pow-Sang, A. Cantor, and W. Janssen, Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma, J. Urol., 167(5): 1995–2000, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• P. Thompson, M. Fishman, J. Seigne, M. Dunn, W. Janssen, R. Smilee, M.J. Farmelo, D. Noyes, J. Pow Sang, and S. Antonia, Phase II study of B7-1 gene-modified autologous tumour cell vaccine and subcutaneous IL-2 for patients with stage IV renal cell carcinoma (RCC). J. Clin. Oncol., 23: 4502, 2005. [CSA]
   Google Scholar
• B.J. Drucker, Renal cell carcinoma: Current status and future prospects, Cancer Treat. Rev., 31(7): 536–545, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• I. Komenaka, H. Hoerig, and H.L. Kaufman, Immunotherapy for melanoma, Clin. Dermatol., 22(3): 251–265, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• I. Hara, H. Nguyen, Y. Takechi, B. Gansbacher, P.B. Chapman, and A.N. Houghton, Rejection of mouse melanoma elicited by local secretion of interleukin-2: Implicating macrophages without T cells or natural killer cells in tumor rejection, Int. J. Cancer, 61(2): 253–260, 1995. [CSA]
   Google Scholar
• K. Zatloukal, A. Schneeberger, M. Berger, W. Schmidt, F. Koszik, R. Kutil, M. Cotten, E. Wagner, M. Buschle, G. Maass, , et al., Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters, J. Immunol., 154(7): 3406–3419, 1995. [CSA]
   Google Scholar
• B. Gansbacher, K. Zier, B. Daniels, K. Cronin, R. Bannerji, and E. Gilboa, Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity, J. Exp. Med., 172(4): 1217–1224, 1990. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• E.R. Fearon, D.M. Pardoll, T. Itaya, P. Golumbek, H.I. Levitsky, J.W. Simons, H. Karasuyama, B. Vogelstein, and P. Frost, Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response, Cell, 60(3): 397–403, 1990. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D.B. Moody, J.C. Robinson, C.M. Ewing, A.J. Lazenby, and W.B. Isaacs, Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo, Prostate, 24(5): 244–251, 1994. [CSA]
   Google Scholar
• R. Bannerji, C.D. Arroyo, C. Cordon-Cardo, and E. Gilboa, The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity, J. Immunol., 152(5): 2324–2332, 1994. [CSA]
   Google Scholar
• G. Maass, W. Schmidt, M. Berger, F. Schilcher, F. Koszik, A. Schneeberger, G. Stingl, M.L. Birnstiel, and T. Schweighoffer, Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: Three consecutive stages may be required for successful tumor vaccination, Proc. Natl. Acad. Sci. U.S.A., 92(12): 5540–5544, 1995. [CSA]
   Google Scholar
• H. Veelken, A. Mackensen, M. Lahn, G. Kohler, D. Becker, B. Franke, U. Brennscheidt, P. Kulmburg, F.M. Rosenthal, H. Keller, J. Hasse, W. Schultze-Seemann, E.H. Farthmann, R. Mertelsmann, and A. Lindemann, A phase-I Clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer, Int. J. Cancer, 70(3): 269–277, 1997. [CSA], [CROSSREF]
   Google Scholar
• S. Osanto, P.P. Schiphorst, N.I. Weijl, N. Dijkstra, A. Van Wees, N. Brouwenstein, N. Vaessen, J. H. Van Krieken, J. Hermans, F.J. Cleton, and P.I. Schrier, Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line, Hum. Gene Ther., 11(5): 739–750, 2000. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• F. Arienti, J. Sule-Suso, F. Belli, L. Mascheroni, L. Rivoltini, C. Melani, M. Maio, N. Cascinelli, M.P. Colombo, and G. Parmiani, Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells, Hum. Gene Ther., 7(16): 1955–1963, 1996. [CSA]
   Google Scholar
• K. Palmer, J. Moore, M. Everard, J.D. Harris, S. Rodgers, R.C. Rees, A.K. Murray, R. Mascari, J. Kirkwood, P.G. Riches, C. Fisher, J.M. Thomas, M. Harries, S.R. Johnston, M.K. Collins, and M.E. Gore, Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma, Hum. Gene. Ther., 10(8): 1261–1268, 1999. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M. Maio, E. Fonsatti, E. Lamaj, M. Altomonte, I. Cattarossi, C. Santantonio, C. Melani, F. Belli, F. Arienti, M.P. Colombo, and G. Parmiani, Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells, Cancer Immunol. Immunother., 51(1): 9–14, 2002. [CSA], [CROSSREF]
   Google Scholar
• F. Belli, F. Arienti, J. Sule-Suso, C. Clemente, L. Mascheroni, A. Cattelan, C. Santantonio, G.F. Gallino, C. Melani, S. Rao, M.P. Colombo, M. Maio, N. Cascinelli, and G. Parmiani, Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability, Cancer Immunol. Immunother., 44(4): 197–203, 1997. [CSA], [CROSSREF]
   Google Scholar
• G. Pizza, C. De Vinci, G. Lo Conte, A. Mazzuca, V. Di Maio, S. Ratini, G. Severini, L. Busutti, A.P. Palareti, A. Gulino, A. Vacca, L. Melchiorri, M. Ferrari, L. Giacomelli, O.R. Baricordi, S. Forzini, and R. Capanna, Allogeneic gene-modified tumour cells in metastatic kidney cancer. Report II, Folia Biol. (Praha), 50(6): 175–183, 2004. [CSA]
   Google Scholar
• F. Pericle, M. Giovarelli, M.P. Colombo, G. Ferrari, P. Musiani, A. Modesti, F. Cavallo, F. Di Pierro, F. Novelli, and G. Forni, An efficient Th2-type memory follows CD8 + lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4, J. Immunol., 153(12): 5659–5673, 1994. [CSA]
   Google Scholar
• R.I. Tepper, P.K. Pattengale, and P. Leder, Murine interleukin-4 displays potent anti-tumor activity in vivo, Cell, 57(3): 503–512, 1989. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• P.T. Golumbek, A.J. Lazenby, H.I. Levitsky, L.M. Jaffee, H. Karasuyama, M. Baker, and D.M. Pardoll, Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4, Science, 254(5032): 713–716, 1991. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• R.I. Tepper, R.L. Coffman, and P. Leder, An eosinophil-dependent mechanism for the antitumor effect of interleukin-4, Science, 257(5069): 548–551, 1992. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J. Eguchi, N. Kuwashima, M. Hatano, F. Nishimura, J.E. Dusak, W.J. Storkus, and H. Okada, IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity, J. Immunol., 174(11): 7194–7201, 2005. [CSA]
   Google Scholar
• F. Arienti, F. Belli, F. Napolitano, J. Sule-Suso, A. Mazzocchi, G.F. Gallino, A. Cattelan, C. Santantonio, L. Rivoltini, C. Melani, M.P. Colombo, N. Cascinelli, M. Maio, and G. Parmiani, Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells, Hum. Gene Ther., 10(18): 2907–2916, 1999. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• H. Ikeda, L.J. Old, and R.D. Schreiber, The roles of IFN gamma in protection against tumor development and cancer immunoediting, Cytokine Growth Factor Rev., 13(2): 95–109, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Z. Abdel-Wahab, M. Dar, S. Osanto, T. Fong, C.E. Vervaert, D. Hester, D. Jolly, and H.F. Seigler, Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon, Cancer Gene Ther., 4(1): 33–41, 1997. [CSA]
   Google Scholar
• R.S. Wu, J.J. Kobie, D.G. Besselsen, T.C. Fong, V.D. Mack, J.A. McEarchern, and E.T. Akporiaye, Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma, Cancer Immunol. Immunother., 50(5): 229–240, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Y. Watanabe, K. Kuribayashi, S. Miyatake, K. Nishihara, E. Nakayama, T. Taniyama, and T. Sakata, Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity, Proc. Natl. Acad. Sci. U.S.A., 86(23): 9456–9460, 1989. [CSA], [CROSSREF]
   Google Scholar
• M.M. Dar, Z. Abdel-Wahab, C.E. Vervaert, T. Darrow, J. Barber, and H.F. Seigler, Immunological memory induced by genetically transduced tumor cells, Ann. Surg. Oncol., 3(3): 247–254, 1996. [CSA], [CROSSREF]
   Google Scholar
• F.M. Rosenthal, K. Cronin, R. Bannerji, D.W. Golde, and B. Gansbacher, Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs, Blood, 83(5): 1289–1298, 1994. [CSA]
   PubMed Web of Science ®Google Scholar
• K.S. Zier and B. Gansbacher, Tumour cell vaccines that secrete interleukin-2 (IL-2) and interferon gamma (IFN gamma) are recognised by T cells while resisting destruction by natural killer (NK) cells, Eur. J. Cancer, 32A(8): 1408–1412, 1996. [CSA], [CROSSREF]
   Google Scholar
• Z. Abdel-Wahab, C. Weltz, D. Hester, N. Pickett, C. Vervaert, J.R. Barber, D. Jolly, and H.F. Seigler, A Phase I Clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: Monitoring the humoral immune response, Cancer, 80(3): 401–412, 1997. [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• N. Mach and G. Dranoff, Cytokine-secreting tumor cell vaccines, Curr. Opin. Immunol., 12(5): 571–575, 2000. [CSA], [CROSSREF]
   Google Scholar
• C. De Giovanni, G. Nicoletti, L. Landuzzi, A. Astolfi, S. Croci, A. Comes, S. Ferrini, R. Meazza, M. Iezzi, E. Di Carlo, P. Musiani, F. Cavallo, P. Nanni, and P.L. Lollini, Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine, Cancer Res., 64(11): 4001–4009, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• G.W. Hull, M.A. McCurdy, Y. Nasu, C.H. Bangma, G. Yang, S. Shimura, H.M. Lee, J. Wang, J. Albani, S. Ebara, T. Sato, T.L. Timme, and T.C. Thompson, Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines, Clin. Cancer Res., 6(10): 4101–4109, 2000. [CSA]
   Google Scholar
• Y. Sun, K. Jurgovsky, P. Moller, S. Alijagic, T. Dorbic, J. Georgieva, B. Wittig, and D. Schadendorf, Vaccination with IL-12 gene-modified autologous melanoma cells: PreClinical results and a first Clinical phase I study, Gene Ther., 5(4): 481–490, 1998. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• N. Fuji, H. Fujiwara, Y. Ueda, F. Taniguchi, T. Yoshimura, T. Oka, and H. Yamagishi, Augmentation of local antitumor immunity in the liver by tumor vaccine modified to secrete murine interleukin 12, Gene Ther., 6(6): 1120–1127, 1999. [CSA], [CROSSREF]
   Google Scholar
• H. Ehlken, D. Schadendorf, and S. Eichmuller, Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells, Int. J. Cancer, 108(2): 307–313, 2004. [CSA], [CROSSREF]
   Google Scholar
• P. Moller, H. Moller, Y. Sun, T. Dorbic, B.M. Henz, B. Wittig, and D. Schadendorf, Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells, Cancer Gene Ther., 7(7): 976–984, 2000. [CSA], [CROSSREF]
   Google Scholar
• R. Meazza, P.L. Lollini, P. Nanni, C. De Giovanni, A. Gaggero, A. Comes, M. Cilli, E. Di Carlo, S. Ferrini, and P. Musiani, Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: Effects on tumorigenicity, metastatic potential and immune response, Int. J. Cancer, 87(4): 574–581, 2000. [CSA], [CROSSREF]
   Google Scholar
• H.L. Ma, M.J. Whitters, R.F. Konz, M. Senices, D.A. Young, M.J. Grusby, M. Collins, and K. Dunussi-Joannopoulos, IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma, J. Immunol., 171(2): 608–615, 2003. [CSA]
   PubMed Web of Science ®Google Scholar
• A. Moroz, C. Eppolito, Q. Li, J. Tao, C.H. Clegg, and P.A. Shrikant, IL-21 enhances and sustains CD8 + T cell responses to achieve durable tumor immunity: Comparative evaluation of IL-2, IL-15, and IL-21, J. Immunol., 173(2): 900–909, 2004. [CSA]
   Web of Science ®Google Scholar
• A. Comes, O. Rosso, A.M. Orengo, E. Di Carlo, C. Sorrentino, R. Meazza, T. Piazza, B. Valzasina, P. Nanni, M.P. Colombo, and S. Ferrini, CD25 + regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine, J. Immunol., 176(3): 1750–1758, 2006. [CSA]
   PubMed Web of Science ®Google Scholar
• E. Di Carlo, A. Comes, A.M. Orengo, O. Rosso, R. Meazza, P. Musiani, M.P. Colombo, and S. Ferrini, IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice, J. Immunol., 172(3): 1540–1547, 2004. [CSA]
   PubMed Web of Science ®Google Scholar
• C.H. Lo, S.C. Lee, P.Y. Wu, W.Y. Pan, J. Su, C.W. Cheng, S.R. Roffler, B.L. Chiang, C.N. Lee, C.W. Wu, and M.H. Tao, Antitumor and antimetastatic activity of IL-23, J. Immunol., 171(2): 600–607, 2003. [CSA]
   PubMed Web of Science ®Google Scholar
• S. Oniki, H. Nagai, T. Horikawa, J. Furukawa, M. L. Belladonna, T. Yoshimoto, I. Hara, and C. Nishigori, Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma, Cancer Res., 66(12): 6395–6404, 2006. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Y.Q. Wang, S. Ugai, O. Shimozato, L. Yu, K. Kawamura, H. Yamamoto, T. Yamaguchi, H. Saisho, and M. Tagawa, Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells, Int. J. Cancer, 105(6): 820–824, 2003. [CSA], [CROSSREF]
   Google Scholar
• M. Chiyo, O. Shimozato, L. Yu, K. Kawamura, T. Iizasa, T. Fujisawa, and M. Tagawa, Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals, Int. J. Cancer, 115(3): 437–442, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M. Hisada, S. Kamiya, K. Fujita, M.L. Belladonna, T. Aoki, Y. Koyanagi, J. Mizuguchi, and T. Yoshimoto, Potent antitumor activity of interleukin-27, Cancer Res., 64(3): 1152–1156, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• R. Salcedo, J.K. Stauffer, E. Lincoln, T.C. Back, J.A. Hixon, C. Hahn, K. Shafer-Weaver, A. Malyguine, R. Kastelein, and J.M. Wigginton, IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: Role for CD8 + T cells, J. Immunol., 173(12): 7170–7182, 2004. [CSA]
   Google Scholar
• V.K. Sondak and J.A. Sosman, Results of Clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine, Semin. Cancer Biol., 13(6): 409–415, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• V.K. Sondak, P.Y. Liu, R.J. Tuthill, R.A. Kempf, J.M. Unger, J.A. Sosman, J.A. Thompson, G.R. Weiss, B.G. Redman, J.G. Jakowatz, R.D. Noyes, and L.E. Flaherty, Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Overall results of a randomized trial of the Southwest Oncology Group, J. Clin. Oncol., 20(8): 2058–2066, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• V.K. Sondak, J. Sosman, J.M. Unger, P.Y. Liu, J. Thompson, R. Tuthill, R. Kempf, L. Flaherty, S. O. G. (SWOG). Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035, 2004. [CSA]
   Google Scholar
• M. Fishman and S. Antonia, Specific antitumour vaccine for renal cancer, Lancet, 363(9409): 583–584, 2004. [CSA], [CROSSREF]
   Google Scholar
• S. Kommu, Renal-cell carcinoma: Vaccination and risk of tumour progression, Lancet, 363(9420): 1557; author reply 1557, 2004. [CSA]
   Google Scholar
• M.L. Albert, B. Sauter, and N. Bhardwaj, Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs, Nature, 392(6671): 86–89, 1998. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• R.M. Steinman, S. Turley, I. Mellman, and K. Inaba, The induction of tolerance by dendritic cells that have captured apoptotic cells, J. Exp. Med., 191(3): 411–416, 2000. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• H. Pandha, J. Eaton, R. Greenhalgh, D. Soars, and A. Dalgleish, Immunotherapy of murine prostate cancer using whole tumor cells killed ex vivo by herpes simplex viral thymidine kinase/ganciclovir suicide gene therapy, Cancer Gene Ther., 12(6): 572–578, 2005. [CSA], [CROSSREF]
   Google Scholar
• J.D. Eaton, M.J. Perry, S.M. Todryk, R.A. Mazucco, R.S. Kirby, J.R. Griffiths, and A.G. Dalgleish, Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques, Gene Ther., 8(7): 557–567, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• V. Schirrmacher, Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: Improvement of patient survival based on improved antitumor immune memory, Cancer Immunol. Immunother., 54(6): 587–598, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D. Ockert, V. Schirrmacher, N. Beck, E. Stoelben, T. Ahlert, J. Flechtenmacher, E. Hagmuller, R. Buchcik, M. Nagel, and H.D. Saeger, Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma, Clin. Cancer Res., 2(1): 21–28, 1996. [CSA]
   PubMed Web of Science ®Google Scholar
• W. Bohle, P. Schlag, W. Liebrich, P. Hohenberger, M. Manasterski, P. Moller, and V. Schirrmacher, Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumor-cell vaccine. First Clinical results with tumor-cell vaccines modified with live but avirulent Newcastle disease virus, Cancer, 66(7): 1517–1523, 1990. [CSA]
   Google Scholar
• B.T. Patel, M.B. Lutz, P. Schlag, and V. Schirrmacher, An analysis of autologous T-cell anti-tumour responses in colon-carcinoma patients following active specific immunization (ASI) Int. J. Cancer, 51(6): 878–885, 1992. [CSA]
   Google Scholar
• K. Dredge, J.B. Marriott, S.M. Todryk, G.W. Muller, R. Chen, D.I. Stirling, and A.G. Dalgleish, Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity, J. Immunol., 168(10): 4914–4919, 2002. [CSA]
   PubMed Web of Science ®Google Scholar
• J.P. Machiels, R.T. Reilly, L.A. Emens, A.M. Ercolini, R.Y. Lei, D. Weintraub, F.I. Okoye, and E.M. Jaffee, Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice, Cancer Res., 61(9): 3689–3697, 2001. [CSA]
   PubMed Web of Science ®Google Scholar
• R.A. Prell, L. Gearin, A. Simmons, M. Vanroey, and K. Jooss, The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration, Cancer Immunol. Immunother., 55(10): 1285–1293, 2006. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Y. Chu, L.X. Wang, G. Yang, H.J. Ross, W.J. Urba, R. Prell, K. Jooss, S. Xiong, and H.M. Hu, Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma, J. Immunother., 29(4): 367–380, 2006. [CSA], [CROSSREF]
   Google Scholar
• B. Yu, S. Kusmartsev, F. Cheng, M. Paolini, Y. Nefedova, E. Sotomayor, and D. Gabrilovich, Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer, Clin. Cancer Res., 9(1): 285–294, 2003. [CSA]
   Google Scholar
• T. Hahn, I. Alvarez, J.J. Kobie, L. Ramanathapuram, S. Dial, A. Fulton, D. Besselsen, E. Walker, and E. T. Akporiaye, Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer, Int. J. Cancer, 118(9): 2220–2231, 2006. [CSA], [CROSSREF]
   Google Scholar
• A.R. Haas, J. Sun, A. Vachani, A.F. Wallace, M. Silverberg, V. Kapoor, and S.M. Albelda, Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine, Clin. Cancer Res., 12(1): 214–222, 2006. [CSA], [CROSSREF]
   Google Scholar
• L.J. Jia, H.M. Xu, D.Y. Ma, Q.G. Hu, X.F. Huang, W.H. Jiang, S.F. Li, K.Z. Jia, Q.L. Huang, and Z.C. Hua, Enhanced therapeutic effect by combination of tumor-targeting Salmonella and endostatin in murine melanoma model, Cancer Biol. Ther., 4(8): 840–845, 2005. [CSA]
   PubMed Web of Science ®Google Scholar
• B.I. Rini, V. Weinberg, L. Fong, S. Conry, R.M. Hershberg, and E.J. Small, Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy, Cancer, 107(1): 67–74, 2006. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• S. Demaria, N. Bhardwaj, W.H. McBride, and S.C. Formenti, Combining radiotherapy and immunotherapy: A revived partnership, Int. J. Radiat. Oncol. Biol. Phys., 63(3): 655–666, 2005. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar